| Company: MEI Pharma Inc. Symbol: MEIP:US Length: 00:25:55 |
Presenter: Dr. Dan Gold, President & CEO Occasion: Richmond Club Lunch, Toronto |
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.
Additional Information
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.
Head Office:
Additional Information
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.
Head Office:
MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, CA 92130
(858) 369-7100